ALN-PNP

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Genetic Risk FactorHealthy VolunteersMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)

Phase 1

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

RecruitingNCT05648214

Regeneron PharmaceuticalsHealthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Start: 2022-12-27End: 2027-08-10Target: 156Updated: 2025-12-22

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

CompletedNCT06024408

Regeneron PharmaceuticalsGenetic Risk Factor, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)

Start: 2024-05-21End: 2025-07-07Updated: 2025-07-31